Iterum Therapeutics (ITRM) Price & Analysis

Compare

899 Followers

ITRM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.66 - $3.02

Previous CloseN/A

Volume220.96K

Average Volume (3M)1.04M

Market Cap

$37.10M

Enterprise Value$59.27M

Total Cash (Recent Filing)$13.03M

Total Debt (Recent Filing)$32.56M

Price to Earnings (P/E)―

Beta1.85

Next Earnings

Nov 07, 2025

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding44,656,906

10 Day Avg. Volume989,222

30 Day Avg. Volume1,035,699

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.60

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-46.41

Enterprise Value/Ebitda-2.91

Forecast

1Y Price Target

$7.00

Price Target Upside845.95% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Intellectual PropertyORLYNVAH is covered by robust intellectual property protection extending into 2039.

Product LaunchThe commercial launch of ORLYNVAH is set to take place with support from a partnership with EVERSANA for sales and commercial operations in the US.

Product SuperiorityORLYNVAH has demonstrated superiority to conventional antibiotics in late-stage clinical trials, providing a strong competitive edge.

Bears Say

Financial PerformanceIterum reported 1Q25 results with a net loss of ($4.9M) and ended the period with $12.7M in cash, excluding additional financing.

Market CompetitionA key challenge for Iterum may have been the overhang of the impending approval of Glaxo's gepotidacin, which could impact market dynamics.

Iterum Therapeutics News

Iterum Therapeutics announces U.S. commercial launch of ORLYNVAH

Iterum Therapeutics (ITRM) announced the U.S. commercial launch of ORLYNVAH oral tablets. The Food and Drug Administration approved...

4d ago

ITRM

Iterum Therapeutics reports Q2 non-GAAP EPS (13c) vs. (23c) last year

“We are on track to launch ORLYNVAH this month for the treatment of uncomplicated urinary tract infections,” said...

19d ago

ITRM

Iterum Therapeutics sees cash runway into 2026

Cash and cash equivalents were $13.0 million as of June 30, 2025. Based on Iterum’s current operating plan,...

19d ago

ITRM

Iterum Therapeutics Launches New Antibiotic ORLYNVAH

Iterum Therapeutics ( ($ITRM) ) has issued an update. On August 20, 2025, Iterum Therapeutics announced the U.S....

4d ago

ITRM

Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges

Iterum Therapeutics (($ITRM)) has held its Q2 earnings call. Read on for the main highlights of the call....

17d ago

ITRM

Buy Rating for Iterum Therapeutics: Strategic Positioning and Growth Potential with ORLYNVAH Launch

Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Iterum Therapeutics, retaining the price target of...

17d ago

ITRM

Iterum Therapeutics Prepares for ORLYNVAH™ Launch

Iterum Therapeutics ( ($ITRM) ) has released its Q2 earnings. Here is a breakdown of the information Iterum...

18d ago

ITRM

Iterum Therapeutics Signs Manufacturing Agreement with ACS Dobfar

Iterum Therapeutics ( ($ITRM) ) just unveiled an announcement. On July 29, 2025, Iterum Therapeutics International Limited entered...

19d ago

ITRM

Iterum Therapeutics Sets AGM Date for September 2025

Iterum Therapeutics ( ($ITRM) ) just unveiled an announcement. Iterum Therapeutics has announced that its 2025 Annual General...

1M ago

ITRM

Iterum Therapeutics appoints Coyne as CCO

Iterum Therapeutics (ITRM) announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer,...

2M ago

ITRM

Iterum Therapeutics announces publication of REASSURE trial in NEJM Evidence

Iterum Therapeutics (ITRM) reported that NEJM Evidence published results from its REASSURE Phase 3 clinical trial comparing oral...

2M ago

ITRM

Iterum Therapeutics: Strategic Positioning and Growth Potential with ORLYNVAH Launch

In a report released today, Matthew Keller from H.C. Wainwright reiterated a Buy rating on Iterum Therapeutics (ITRM...

2M ago

ITRM

Iterum Therapeutics Partners with Eversana for US Launch

Iterum Therapeutics ( ($ITRM) ) has provided an announcement. On June 6, 2025, Iterum Therapeutics US Limited entered...

2M ago

ITRM

Iterum Therapeutics announces partnership for commercialization services

Iterum Therapeutics (ITRM) reported that it entered into a Product Commercialization Agreement with EVERSANA Life Science Services for...

2M ago

ITRM

ITRM FAQ

What was Iterum Therapeutics Plc’s price range in the past 12 months?

Iterum Therapeutics Plc lowest stock price was $0.66 and its highest was $3.02 in the past 12 months.

What is Iterum Therapeutics Plc’s market cap?

Iterum Therapeutics Plc’s market cap is $37.10M.

When is Iterum Therapeutics Plc’s upcoming earnings report date?

Iterum Therapeutics Plc’s upcoming earnings report date is Nov 07, 2025 which is in 75 days.

How were Iterum Therapeutics Plc’s earnings last quarter?

Iterum Therapeutics Plc released its earnings results on Aug 05, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.02.

Is Iterum Therapeutics Plc overvalued?

According to Wall Street analysts Iterum Therapeutics Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Iterum Therapeutics Plc pay dividends?

Iterum Therapeutics Plc does not currently pay dividends.

What is Iterum Therapeutics Plc’s EPS estimate?

Iterum Therapeutics Plc’s EPS estimate is -0.11.

How many shares outstanding does Iterum Therapeutics Plc have?

Iterum Therapeutics Plc has 44,656,906 shares outstanding.

What happened to Iterum Therapeutics Plc’s price movement after its last earnings report?

Iterum Therapeutics Plc reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went down -1.408%.

Which hedge fund is a major shareholder of Iterum Therapeutics Plc?

Currently, no hedge funds are holding shares in ITRM

Iterum Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

607.06%

Trailing 12-Months

Asset Growth

139.97%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Iterum Therapeutics Plc

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Iterum Therapeutics (ITRM) Earnings & Revenues

Historic Earnings Reports

ITRM Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlights significant progress with the early launch of ORLYNVAH, a large addressable market, secured manufacturing, extended financial flexibility, and strong market protection. However, increased operating expenses, rising net loss, and the need for additional share authorization highlight financial challenges. There is a balanced sentiment with notable achievements and challenges.View all ITRM earnings summaries

ITRM Stock 12 Month Forecast

Average Price Target

$7.00

▲(845.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.73,1.366153846153846,2.002307692307692,2.638461538461538,3.2746153846153843,3.91076923076923,4.546923076923076,5.183076923076923,5.819230769230769,6.455384615384615,7.091538461538461,7.7276923076923065,8.363846153846152,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.73,1.2123076923076923,1.6946153846153846,2.1769230769230767,2.659230769230769,3.1415384615384614,3.6238461538461535,4.1061538461538465,4.588461538461538,5.07076923076923,5.553076923076922,6.035384615384615,6.5176923076923075,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.73,1.0584615384615383,1.3869230769230767,1.7153846153846153,2.043846153846154,2.3723076923076922,2.7007692307692306,3.029230769230769,3.3576923076923073,3.6861538461538457,4.014615384615384,4.343076923076922,4.671538461538461,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.59,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >